Back to Journals » OncoTargets and Therapy » Volume 5 » default

OncoTargets and Therapy


Archive: Volume 5, 2012

Endoscopy-verified occult subependymal dissemination of glioblastoma and brain metastasis undetected by MRI: prognostic significance

Iacoangeli M, Di Rienzo A, Colasanti R, Zizzi A, Gladi M, Alvaro L, Nocchi N, Di Somma LG, Scarpelli M, Scerrati M

OncoTargets and Therapy 2012, 5:449-456

Published Date: 13 December 2012

Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib

Xu F, Wu J, Xue C, Zhao Y, Jiang W, Lin L, Wu X, Lu Y, Bai H, Xu J, Zhu G, Zhang L

OncoTargets and Therapy 2012, 5:439-447

Published Date: 12 December 2012

Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions

Karanikas M, Machairiotis N, Zarogoulidis P, Stylianaki A, Courcoutsakis N, Mitrakas A, Touzopoulos P, Lyratzopoulos N, Kouklakis G, Spanoudakis M, Polychronidis A

OncoTargets and Therapy 2012, 5:433-438

Published Date: 12 December 2012

Impact of CHK2-small interfering RNA on CpG ODN7909-enhanced radiosensitivity in lung cancer A549 cells

Chen W, Liu XQ, Qiao TK, Yuan SJ

OncoTargets and Therapy 2012, 5:425-431

Published Date: 3 December 2012

Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma

Cangemi G, Reggiardo G, Barco S, Barbagallo L, Conte M, D'Angelo P, Bianchi M, Favre C, Galleni B, Melioli G, Haupt R, Garaventa A, Corrias MV

OncoTargets and Therapy 2012, 5:417-423

Published Date: 30 November 2012

Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs

Fernandes I, Pacheco TR, Costa A, Santos AC, Fernandes AR, Santos M, Oliveira AG, Casimiro S, Quintela A, Fernandes A, Ramos M, Costa L

OncoTargets and Therapy 2012, 5:409-416

Published Date: 28 November 2012

Abnormal expression of PER1 circadian-clock gene in oral squamous cell carcinoma

Chen R, Yang K, Zhao NB, Zhao D, Chen D, Zhao CR, Tang H

OncoTargets and Therapy 2012, 5:403-407

Published Date: 27 November 2012

β-blockers: a novel class of antitumor agents

Ji Y, Chen S, Xiao X, Zheng S, Li K

OncoTargets and Therapy 2012, 5:391-401

Published Date: 26 November 2012

The utility of tumor markers CA 125, CA 15-3, and CA 19-9 in assessing the response to therapy in pulmonary and pleural tuberculosis

Tasci C, Ozkaya S, Ozkara B, Tozkoparan E, Ozkan M, Karadurmus N, Serdar M, Balkan A, Bilgic H

OncoTargets and Therapy 2012, 5:385-390

Published Date: 22 November 2012

Cancer stem cells in head and neck cancer

Allegra E, Trapasso S

OncoTargets and Therapy 2012, 5:375-383

Published Date: 21 November 2012

Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma

Hountis P, Foukas PG, Matthaios D, Kefala M, Chelis L, Pantelidaki A, Panayiotides IG, Karakitsos P, Kakolyris S

OncoTargets and Therapy 2012, 5:363-373

Published Date: 21 November 2012

Rare synchronous association of vestibular schwannoma and indolent insular oligodendroglioma in a patient without neurofibromatosis: controversial issue of timing for surgical treatment of asymptomatic low-grade gliomas

Iacoangeli M, Di Rienzo A, Colasanti R, Alvaro L, Nocchi N, Polonara G, Di Somma LG, Zizzi A, Scarpelli M, Scerrati M

OncoTargets and Therapy 2012, 5:357-361

Published Date: 19 November 2012

The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution

Zhang J, Huang Y, Li X, Guo Y, Zhao Y, Xue C, Hu Z, Zhang L, Zhao H

OncoTargets and Therapy 2012, 5:349-355

Published Date: 15 November 2012

Tumor necrosis factor signaling is implicated in intestinal mucosal injury of cancer cachexic mice

Jia Y, Tian W, Cui B

OncoTargets and Therapy 2012, 5:343-348

Published Date: 12 November 2012

A study of mifepristone/IFN-γ-induced apoptosis of human cholangiocarcinoma cell line FRH-0201 in vitro

Sun QL, Zhang XG, Xing QT, Ding P, Feng JB, Wu XP, Wang ZM

OncoTargets and Therapy 2012, 5:335-342

Published Date: 9 November 2012

Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance

Chen HF, Wu TQ, Li ZY, Shen HS, Tang JQ, Fu WJ, Yuan ZG, Hou J

OncoTargets and Therapy 2012, 5:329-334

Published Date: 7 November 2012

Targeted treatments for cervical cancer: a review

Peralta-Zaragoza O, Bermúdez-Morales VH, Pérez-Plasencia C, Salazar-León J, Gómez-Cerón C, Madrid-Marina V

OncoTargets and Therapy 2012, 5:315-328

Published Date: 2 November 2012

γ-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer

Matthaios D, Foukas PG, Kefala M, Hountis P, Trypsianis G, Panayiotides IG, Chatzaki E, Pantelidaki E, Bouros D, Karakitsos P, Kakolyris S

OncoTargets and Therapy 2012, 5:309-314

Published Date: 30 October 2012

Current and emerging treatment options for nasopharyngeal carcinoma

Spratt DE, Lee N

OncoTargets and Therapy 2012, 5:297-308

Published Date: 23 October 2012

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology

Sherrill B, Kaye JA, Sandin R, Cappelleri JC, Chen C

OncoTargets and Therapy 2012, 5:287-296

Published Date: 23 October 2012

Crosstalk between EGFR and integrin affects invasion and proliferation of gastric cancer cell line, SGC7901

Dan L, Jian D, Na L, Xiaozhong W

OncoTargets and Therapy 2012, 5:271-277

Published Date: 23 October 2012

Research progress on criteria for discontinuation of EGFR inhibitor therapy

Zhuang HQ, Yuan ZY, Wang J, Wang P, Zhao LJ, Zhang BL

OncoTargets and Therapy 2012, 5:263-270

Published Date: 15 October 2012

Clinicopathological and prognostic significance of epithelial mesenchymal transition-related protein expression in intrahepatic cholangiocarcinoma

Yao X, Wang X, Wang Z, Dai L, Zhang G, Yan Q, Zhou W

OncoTargets and Therapy 2012, 5:255-261

Published Date: 12 October 2012

Helical tomotherapy provides efficacy similar to that of intensity-modulated radiation therapy with dosimetric benefits for endometrial carcinoma

Hsieh CH, Shueng PW, Hsiao SM, Wei MC, Wu WY, Sun HD, Tien HJ, Wang LY, Hsieh YP

OncoTargets and Therapy 2012, 5:245-253

Published Date: 1 October 2012

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma

Fostier K, De Becker A, Schots R

OncoTargets and Therapy 2012, 5:237-244

Published Date: 28 September 2012

Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival

Zarogoulidis P, Mavroudi M, Porpodis K, Domvri K, Sakkas A, Machairiotis N, Stylianaki A, Tsiotsios A, Courcoutsakis N, Zarogoulidis K

OncoTargets and Therapy 2012, 5:231-236

Published Date: 27 September 2012

Denosumab: a new option in the treatment of bone metastases from urological cancers

Yuasa T, Yamamoto S, Urakami S, Fukui I, Yonese J

OncoTargets and Therapy 2012, 5:221-229

Published Date: 21 September 2012

Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia

Bai J, Guo A, Hong Z, Kuai W

OncoTargets and Therapy 2012, 5:213-219

Published Date: 21 September 2012

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer

Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S

OncoTargets and Therapy 2012, 5:199-211

Published Date: 24 September 2012

Evaluation of therapeutic effect of tumor-targeted therapy

Li XF, Li MD, Shen H, Fang XF, Huang PT, Yuan Y

OncoTargets and Therapy 2012, 5:191-198

Published Date: 17 September 2012

Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial

Yamamoto D, Iwase S, Tsubota Y, Sueoka N, Yamamoto C, Kitamura K, Odagiri H, Nagumo Y

OncoTargets and Therapy 2012, 5:185-189

Published Date: 17 September 2012

Expression of transient receptor potential channel 6 in cervical cancer

Wan Q, Zheng A, Liu XJ, Chen YL, Han L

OncoTargets and Therapy 2012, 5:171-176

Published Date: 3 September 2012

Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer

Rich TA, Winter K, Safran H, Hoffman JP, Erickson B, Anne PR, Myerson RJ, Cline-Burkhardt VJ, Perez K, Willett C

OncoTargets and Therapy 2012, 5:161-170

Published Date: 23 August 2012

Recombinant human decorin suppresses liver HepG2 carcinoma cells by p21 upregulation

Zhang Y, Wang Y, Du Z, Wang Q, Wu M, Wang X, Wang L, Cao L, Hamid AS, Zhang G

OncoTargets and Therapy 2012, 5:143-152

Published Date: 13 August 2012

The role of EGFR-targeting strategies in the treatment of head and neck cancer

Dequanter D, Shahla M, Paulus P, Lothaire PH

OncoTargets and Therapy 2012, 5:127-131

Published Date: 27 July 2012

Targeted therapy for esophagogastric cancers: a review

Khattak MA, Martin HL, Karapetis CS

OncoTargets and Therapy 2012, 5:91-102

Published Date: 21 May 2012

Targeting bladder tumor cells in voided urine of Chinese patients with FITC-CSNRDARRC peptide ligand

Jia XY, Yu Q, Zhang ZH, Yang XF

OncoTargets and Therapy 2012, 5:85-90

Published Date: 7 May 2012

Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment

Pham PV, Vu NB, Duong TT, Nguyen TT, Truong NH, Phan NLC, Vuong TG, Pham VQ, Nguyen HM, Nguyen KT, Nguyen NT, Nguyen KG, Khat LT, Le DV, Truong KD, Phan NK

OncoTargets and Therapy 2012, 5:77-84

Published Date: 7 May 2012

Hedgehog pathway as a drug target: Smoothened inhibitors in development

Lin TL, Matsui W

OncoTargets and Therapy 2012, 5:47-58

Published Date: 9 March 2012

Targeted agents for the treatment of metastatic melanoma

Monzon JG, Dancey J

OncoTargets and Therapy 2012, 5:31-46

Published Date: 5 March 2012

Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation

Jacob NK, Cooley JV, Shirai K, Chakravarti A

OncoTargets and Therapy 2012, 5:7-20

Published Date: 15 February 2012